Blog

Updated Guideline on Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer – ASCO

ASCO/X

May 8, 2025, 10:41

Updated Guideline on Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer – ASCO

American Society of Clinical Oncology (ASCO) shared a post on LinkedIn:

“We issued a guideline update on Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.

For men whose castration-sensitive prostate cancer was previously treated with systemic therapy, the type of that prior treatment will guide the selection of their next therapy for metastatic castration-resistant prostate cancer (mCRPC).

It’s recommended that androgen-deprivation therapy be continued without stopping for patients with mCRPC.

Read full article.”

Updated Guideline on Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer - ASCO

More posts featuring American Society of Clinical Oncology on OncoDaily.

American Society of Clinical Oncology androgen deprivation therapy ASCO cancer fight against cancer Global fight against cancer mCRPC metastatic castration-resistant prostate cancer OncoDaily Oncology prostate cancer systemic therapy

USA vs Europe: Who Does Cancer Screening Better?

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action